SUTRO BIOPHARMA, INC. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
SUTRO BIOPHARMA, INC. (STRO) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax of $43.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-06-30 was $43.00K.
- SUTRO BIOPHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-03-31 was -$120.00K.
- SUTRO BIOPHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-12-31 was -$14.00K.
- SUTRO BIOPHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-09-30 was $46.00K, a 82.90% decline year-over-year.
- SUTRO BIOPHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2025 was -$20.00K, a 211.11% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2024 was $18.00K, a 97.18% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2023 was $639.00K.
- SUTRO BIOPHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2022 was -$304.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.00K 10-Q · filed 2026-08-12 | -$77.00K 10-Q · filed 2026-08-12 | -$91.00K derived: sum of 3 quarters · filed 2026-08-12 | -$45.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$120.00K 10-Q · filed 2026-08-12 | -$134.00K derived: sum of 2 quarters · filed 2026-08-12 | -$88.00K derived: sum of 3 quarters · filed 2026-08-12 | -$92.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $32.00K derived: sum of 2 quarters · filed 2026-03-23 | $28.00K derived: sum of 3 quarters · filed 2026-08-12 | -$20.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $46.00K 10-Q · filed 2025-11-06 | $42.00K derived: sum of 2 quarters · filed 2026-08-12 | -$6.00K 10-Q · filed 2025-11-06 | -$73.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$4.00K 10-Q · filed 2026-08-12 | -$52.00K 10-Q · filed 2026-08-12 | -$119.00K derived: sum of 3 quarters · filed 2026-08-12 | $150.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$48.00K 10-Q · filed 2026-08-12 | -$115.00K derived: sum of 2 quarters · filed 2026-08-12 | $154.00K derived: sum of 3 quarters · filed 2026-08-12 | $104.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2024-12-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $202.00K derived: sum of 2 quarters · filed 2026-03-23 | $152.00K derived: sum of 3 quarters · filed 2026-03-23 | $18.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $269.00K 10-Q · filed 2025-11-06 | $219.00K derived: sum of 2 quarters · filed 2025-11-06 | $85.00K 10-Q · filed 2025-11-06 | $99.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$50.00K 10-Q · filed 2025-11-06 | -$184.00K 10-Q · filed 2025-08-07 | -$170.00K derived: sum of 3 quarters · filed 2025-11-06 | -$179.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | -$134.00K 10-Q · filed 2025-11-06 | -$120.00K derived: sum of 2 quarters · filed 2025-11-06 | -$129.00K derived: sum of 3 quarters · filed 2025-11-06 | -$6.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.00K derived: sum of 2 quarters · filed 2025-03-13 | $128.00K derived: sum of 3 quarters · filed 2025-03-13 | $639.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$9.00K 10-Q · filed 2024-11-13 | $114.00K derived: sum of 2 quarters · filed 2024-11-13 | $625.00K 10-Q · filed 2024-11-13 | $1.34M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $123.00K 10-Q · filed 2024-11-13 | $634.00K 10-Q · filed 2024-08-13 | $1.35M derived: sum of 3 quarters · filed 2025-03-13 | $1.37M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $511.00K 10-Q · filed 2024-11-13 | $1.23M derived: sum of 2 quarters · filed 2025-03-13 | $1.25M derived: sum of 3 quarters · filed 2025-03-13 | $1.04M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $718.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $738.00K derived: sum of 2 quarters · filed 2025-03-13 | $534.00K derived: sum of 3 quarters · filed 2025-03-13 | -$304.00K 10-K · filed 2025-03-13 |
| 2022-09-30 | $20.00K 10-Q · filed 2023-11-13 | -$184.00K derived: sum of 2 quarters · filed 2023-11-13 | -$1.02M 10-Q · filed 2023-11-13 | -$1.31M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | -$204.00K 10-Q · filed 2023-11-13 | -$1.04M 10-Q · filed 2023-08-10 | -$1.33M derived: sum of 3 quarters · filed 2024-03-25 | -$1.31M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | -$838.00K 10-Q · filed 2023-11-13 | -$1.12M derived: sum of 2 quarters · filed 2024-03-25 | -$1.11M derived: sum of 3 quarters · filed 2024-03-25 | -$1.15M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | -$284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$269.00K derived: sum of 2 quarters · filed 2024-03-25 | -$314.00K derived: sum of 3 quarters · filed 2024-03-25 | -$443.00K 10-K · filed 2024-03-25 |
| 2021-09-30 | $15.00K 10-Q · filed 2022-11-08 | -$30.00K derived: sum of 2 quarters · filed 2022-11-08 | -$159.00K 10-Q · filed 2022-11-08 | -$267.00K derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | -$45.00K 10-Q · filed 2022-11-08 | -$174.00K 10-Q · filed 2022-08-08 | -$282.00K derived: sum of 3 quarters · filed 2023-03-30 | -$443.00K derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | -$129.00K 10-Q · filed 2022-11-08 | -$237.00K derived: sum of 2 quarters · filed 2023-03-30 | -$398.00K derived: sum of 3 quarters · filed 2023-03-30 | -$28.00K derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | -$108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$269.00K derived: sum of 2 quarters · filed 2023-03-30 | $101.00K derived: sum of 3 quarters · filed 2023-03-30 | -$36.00K 10-K · filed 2023-03-30 |
| 2020-09-30 | -$161.00K 10-Q · filed 2021-11-10 | $209.00K derived: sum of 2 quarters · filed 2021-11-10 | $72.00K 10-Q · filed 2021-11-10 | $14.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $370.00K 10-Q · filed 2021-11-10 | $233.00K 10-Q · filed 2021-08-09 | $175.00K derived: sum of 3 quarters · filed 2022-02-28 | $185.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$137.00K 10-Q · filed 2021-11-10 | -$195.00K derived: sum of 2 quarters · filed 2022-02-28 | -$185.00K derived: sum of 3 quarters · filed 2022-02-28 | -$28.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$48.00K derived: sum of 2 quarters · filed 2022-02-28 | $109.00K derived: sum of 3 quarters · filed 2022-02-28 | $212.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $10.00K 10-Q · filed 2020-11-05 | $167.00K derived: sum of 2 quarters · filed 2020-11-05 | $270.00K 10-Q · filed 2020-11-05 | $250.00K derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $157.00K 10-Q · filed 2020-11-05 | $260.00K 10-Q · filed 2020-08-06 | $240.00K derived: sum of 3 quarters · filed 2021-03-18 | $213.00K derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $103.00K 10-Q · filed 2020-11-05 | $83.00K derived: sum of 2 quarters · filed 2021-03-18 | $56.00K derived: sum of 3 quarters · filed 2021-03-18 | $56.00K derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$47.00K derived: sum of 2 quarters · filed 2021-03-18 | -$47.00K derived: sum of 3 quarters · filed 2021-03-18 | -$47.00K 10-K · filed 2021-03-18 |
| 2018-09-30 | -$27.00K 10-Q · filed 2019-11-08 | -$27.00K derived: sum of 2 quarters · filed 2019-11-08 | -$27.00K 10-Q · filed 2019-11-08 | -$26.00K derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-14 | $0.00 10-Q · filed 2019-08-14 | $1.00K derived: sum of 3 quarters · filed 2020-03-16 | $6.00K derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 | $1.00K derived: sum of 2 quarters · filed 2020-03-16 | $6.00K derived: sum of 3 quarters · filed 2020-03-16 | |
| 2017-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $6.00K derived: sum of 2 quarters · filed 2020-03-16 | $17.00K 10-K · filed 2020-03-16 | |
| 2017-09-30 | $5.00K 10-Q · filed 2018-11-14 | $16.00K 10-Q · filed 2018-11-14 | ||
| 2016-12-31 | $34.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |